-
May 08, 2013
Amgen really needs the pipeline to come through to support this valuation.
-
February 13, 2013
Amgen (AMGN) recently provided an update on its long-term strategy. The company said that it intends to focus on the ...
-
February 12, 2013
UCB (UCBJF) and Amgen Inc. (AMGN) recently announced their decision to discontinue a phase III program being ...
-
January 31, 2013
Actavis, Inc. (ACT), formerly known as Watson Pharmaceuticals, Inc., recently provided an update on its 2012 ...
-
January 25, 2013
Investing in biotechnology can be exciting, profitable, and loaded with land mines. For every company that hits the ...
-
January 24, 2013
Amgen (AMGN) reported fourth quarter 2012 earnings of $1.39 per share, 4 cents below the Zacks Consensus Estimate. ...
-
January 22, 2013
Amgen (AMGN) is scheduled to report its fourth quarter 2012 results on Jan 23, 2013 after the closing bell. Last ...
-
January 17, 2013
AstraZeneca (AZN) recently announced that the company has created seven positions in the senior executive team. At ...
-
January 16, 2013
Good news flowed in at Bristol-Myers Squibb (BMY) from Canada when Health Canada, the federal department responsible ...
-
January 08, 2013
Biogen Idec (BIIB) recently submitted a Biologics License Application (BLA) seeking US Food and Drug Administration ...
-
January 07, 2013
Biotechnology company, BioMimetic Therapeutics, Inc. (BMTI) recently announced that it has started enrolling ...
-
December 19, 2012
Actelion (ALIOF) recently announced positive results from a phase II study on its S1P1 modulator, ponesimod. ...
-
December 12, 2012
Align Technology's (ALGN) third quarter 2012 results were dismal with the company reporting revenues and adjusted ...
-
December 12, 2012
Amgen Inc's (AMGN) third quarter EPS of $1.66 per share was 23 cents above the Zacks Consensus Estimate and 19.4% ...
-
November 28, 2012
Abbott Labs (ABT) recently received approval for yet another indication of Humira (adalimumab). The European ...
-
November 16, 2012
With the election over, many investors assumed that one of the key risk events for U.S. markets was past us. ...
-
November 15, 2012
Celgene Corporation (CELG) recently announced encouraging results on its candidate apremilast from a phase III study ...
-
November 15, 2012
Recently, AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that their type II diabetes candidate, Forxiga ...
-
November 05, 2012
Teva has restructuring and growth opportunities, but the risk is still elevated.
-
October 26, 2012
AstraZeneca's (AZN) third quarter 2012 core earnings of $1.51 per American Depositary Share (ADS) beat the Zacks ...
